https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-28 / AIDS 2006 Feb;20(4):627-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-28 / AIDS 2006 Feb;20(4):627-302006-02-28 00:00:002019-02-15 09:15:17Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-15 / J. Immunol. 2006 Feb;176(4):2134-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-15 / J. Immunol. 2006 Feb;176(4):2134-412006-02-15 00:00:002019-02-15 09:17:44Hyperthermia enhances CTL cross-priming
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-10 / Cell. Immunol. 2005 Nov;238(1):61-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-10 / Cell. Immunol. 2005 Nov;238(1):61-62006-02-10 00:00:002019-02-15 09:03:07Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-07 / Curr. Opin. Immunol. 2006 Apr;18(2):201-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-07 / Curr. Opin. Immunol. 2006 Apr;18(2):201-52006-02-07 00:00:002019-02-15 09:24:17Therapeutic cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-04 / Cancer Immunol. Immunother. 2006 Nov;55(11):1309-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-04 / Cancer Immunol. Immunother. 2006 Nov;55(11):1309-192006-02-04 00:00:002019-02-15 08:59:59Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-03 / J. Leukoc. Biol. 2006 Apr;79(4):747-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-03 / J. Leukoc. Biol. 2006 Apr;79(4):747-562006-02-03 00:00:002019-02-15 08:37:30Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-02 / Clin. Immunol. 2006 Apr;119(1):32-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-02 / Clin. Immunol. 2006 Apr;119(1):32-72006-02-02 00:00:002019-02-15 09:15:14Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Clin Cancer Res 2006 Feb;12(3 Pt 1):869-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Clin Cancer Res 2006 Feb;12(3 Pt 1):869-772006-02-01 00:00:002006-02-01 00:00:00Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Cancer Gene Ther. 2006 Feb;13(2):182-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Cancer Gene Ther. 2006 Feb;13(2):182-932006-02-01 00:00:002006-02-01 00:00:00Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-872006-02-01 00:00:002019-02-15 08:48:35Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
